Department of Clinical Microbiology, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Kumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
PLoS Negl Trop Dis. 2022 Aug 4;16(8):e0010129. doi: 10.1371/journal.pntd.0010129. eCollection 2022 Aug.
Lymphatic filariasis (LF) causes chronic morbidity, which usually manifests as lymphedema or hydrocele. Mass drug administration (MDA) began in Kassena Nankana East Municipal (KNEM) and Nabdam, two hotspot districts in the Upper East Region in Ghana, in 2000 and 2005, respectively. This cross-sectional study evaluated the impact of 15 years of MDA on the control of LF as determined by circulating filarial antigen (CFA) and microfilariae assessment in the KNEM and the Nabdam districts.
METHODOLOGY/PRINCIPAL FINDINGS: A total of 7,453 participants from eight sub-districts in the two hotspot districts (KNEM: N = 4604; Nabdam: N = 2849) were recruited into the study. The overall CFA prevalence as determined by the FTS was 19.6% and 12.8% in the KNEM and Nabdam districts, respectively. Manyoro, a sub-district on the border with Burkina Faso, recorded the highest CFA prevalence of 26% in the KNEM. Assessment of microfilariae and Og4C3 antigen was done from 1009 (KNEM: N = 799 (79.2%); Nabdam: N = 210 (20.8%)) randomly selected FTS-positive (N = 885) and FTS-negative (N = 124) individuals. The Og4C3 antigen was found in 22.6%/23.0% of the selected individuals (KNEM/Nabdam), whereas the night blood revealed microfilariae in only 0.7%/0.5%.
CONCLUSIONS/SIGNIFICANCE: Using the WHO endorsed FTS, CFA prevalence exceeded the long-standing <2% threshold-which may need revision and validation. Surprisingly, the Og4C3 ELISA showed positive results in only about one-fifth of the FTS positive samples. However, even this result would not have met the <2% CFA criteria for LF elimination. In contrast, projections from the microfilariae results revealed a halt in LF transmission. The global elimination target was due in 2020 but has been extended to 2030 since this could not be met. Focused MDA intervention intensification on seasonal migrants and non-compliers, and implementation of alternative treatment strategies may suffice for the elimination of the disease.
淋巴丝虫病(LF)会导致慢性发病,通常表现为淋巴水肿或鞘膜积液。大规模药物治疗(MDA)于 2000 年和 2005 年分别在加纳上东部地区的 Kassena Nankana East Municipal(KNEM)和 Nabdam 两个热点地区开始。本横断面研究评估了 15 年 MDA 对通过循环丝状抗原(CFA)和微丝蚴评估在 KNEM 和 Nabdam 地区控制 LF 的影响。
方法/主要发现:共有来自两个热点地区(KNEM:N = 4604;Nabdam:N = 2849)的 8 个分区的 7453 名参与者被招募到该研究中。FTS 确定的总 CFA 患病率分别为 KNEM 区的 19.6%和 Nabdam 区的 12.8%。与布基纳法索接壤的 Manyoro 分区记录的 CFA 患病率最高,为 KNEM 区的 26%。从 1009 名随机选择的 FTS 阳性(KNEM:N = 799(79.2%);Nabdam:N = 210(20.8%))个体中进行了微丝蚴和 Og4C3 抗原检测。在选定的个体中,Og4C3 抗原分别在 22.6%/23.0%(KNEM/Nabdam)中发现,而夜间血液仅在 0.7%/0.5%中发现微丝蚴。
结论/意义:使用世界卫生组织认可的 FTS,CFA 患病率超过了长期存在的<2%阈值-这可能需要修订和验证。令人惊讶的是,只有约五分之一的 FTS 阳性样本的 Og4C3 ELISA 显示阳性结果。然而,即使是这样的结果也不会满足 LF 消除的<2%CFA 标准。相比之下,微丝蚴结果的预测显示 LF 传播已经停止。全球消除目标原定于 2020 年实现,但由于无法实现,已延长至 2030 年。针对季节性移民和不遵守者的集中 MDA 干预强化以及替代治疗策略的实施可能足以消除该疾病。